Breast Implant Cancer
Some breast implants, both saline and silicone, have been linked to an increased risk of cancer called, BIA-ALCL, breast-implant associated anaplastic large cell lymphoma a non-Hodgkin lymphoma of the immune system. The FDA requested that Allergan recall its BIOCELL® textured breast implants and tissue expanders due to increased risk of a rare cancer. Saline and silicone implants, tissue expanders, some implants formerly called McGhan and Inamed are included in the list that follows.
BIA-ALCL is typically found in scar tissue and fluid near the implant, but may spread throughout the body. Patients exhibit late-onset symptoms, such as:
- breast asymmetry
BIA-ALCL can spread throughout the body and can lead to death if not diagnosed early or promptly treated. In most patients, BIA-ALCL is treated successfully with surgery to remove the implant and the scar tissue surrounding the implant; however, some patients may require treatment with chemotherapy and/or radiation therapy. It is critical to have the correct testing, diagnosis and undergo treatment.
According to Dr. Mark W. Clemens II, a plastic surgeon and expert on ALCL at the University of Texas MD Anderson Cancer Center in Houston, “only about 30 percent of plastic surgeons were routinely discussing the cancer with patients” as of 2015. Diagnosis of this type of BIA-ALCL cancer requires a test for a substance called CD30 which is conducted by collecting and examining fluid around the implant. If not tested correctly, the disease can easily be mistaken for others, and doctors may order rounds of unnecessary chemotherapy and radiation for patients that ultimately cause more harm than good while not treating the underlying problem.
Most patients will have spontaneous fluid collection; 40 percent will feel a mass or lump. Diagnosis of BIA-ALCL is possible with a screening test called CD30 and can be missed without adequate screening.
We have been litigating breast implant claims for the past three decades. Contact us at 1-800-814-4540, email firstname.lastname@example.org or fill out the contact form for a free medical legal consultation.
Breast Implant Recalls: Manufacturers & Products
ALLERGAN NATRELLE SALINE-FILLED BREAST IMPLANTS (FORMERLY MCGHAN RTV SALINE-FILLED Mammary Implant) approved under P990074. Textured styles include:
- Style 163 – BIOCELL Textured Shaped Full Height, Full Projection Saline Breast Implants
- Style 168 – BIOCELL Textured Round Moderate Profile Saline Breast Implants, also referred to as 168MP (168 Moderate Profile)
- Style 363 – BIOCELL Textured Shaped Moderate Height, Full Projection Saline Breast Implants, Allergan catalog includes 363LF, or 363 Low Height Full Projection
- Style 468 – BIOCELL Textured Shaped Full Height Moderate Projection Saline Breast Implants
ALLERGAN NATRELLE SILICONE-FILLED TEXTURED BREAST IMPLANTS (FORMERLY INAMED SILICONE-FILLED Breast Implants) approved under P020056. Textured styles include:
- Style 110 – BIOCELL Textured Round Moderate Projection Gel Filled Breast Implants
- Style 115 – BIOCELL Textured Round Midrange Projection Gel Filled Breast Implants
- Style 120 – BIOCELL Textured Round High Projection Gel Filled Breast Implants
- Style TRL – Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled Breast Implants
- Style TRLP – Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled Breast Implants
- Style TRM – Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled Breast Implants
- Style TRF – Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled Breast Implants
- Style TRX – Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled Breast Implants
- Style TCL – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled Breast Implants
- Style TCLP – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled Breast Implants
- Style TCM – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled Breast Implants
- Style TCF – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled Breast Implants
- Style TCX – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled Breast Implants
- Style TSL – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast Implants
- Style TSLP – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast Implants
- Style TSM – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast Implants
- Style TSF – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast Implants
- Style TSX – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast Implants
NATRELLE 410 HIGHLY COHESIVE ANATOMICALLY SHAPED SILICONE FILLED BREAST IMPLANTS APPROVED UNDER P040046. TEXTURED STYLES INCLUDE:
- Style 410FM
- Style 410FF
- Style 410MM
- Style 410 MF
- Style 410 FL
- Style 410 ML
- Style 410 LL
- Style 410 LM
- Style 410 LF
- Style 410 FX
- Style 410 MX
- Style 410 LX
ALLERGAN TISSUE EXPANDERS THAT HAVE BIOCELL TEXTURE originally cleared as:
- Natrelle 133 Plus Tissue Expander (K143354)
- Natrelle 133 Tissue Expander with Suture Tabs (K102806)
Worldwide, 573 cases and 33 deaths from the cancer have been reported, with 481 of the cases clearly attributed to Allergan Biocell implants, the F.D.A. said. Of the 33 deaths, the agency said its data showed that the type of implant was known in 13 cases, and in 12 of those cases the maker was Allergan.
Dow Corning Breast Implant Claims
$50 Million To Be Released
We are not accepting Dow Corning Breast Implant Claims, so contact the SFDCT at their information below. On December 13, 2018, the 6th Circuit Court of Appeals ruled on the Premium Payment Issue authorizing the disbursal of fifty percent of second-priority payments. This Decision pertains to those claimants who did not receive their first 50% payment. Please click here to see the Decision.
ThThe Settlement Facility – Dow Corning Trust (“SF-DCT” or Settlement Facility) is the claims office that processes and pays claims in the Dow Corning breast implant settlement. The Dow Corning Plan provides that the settlement program will terminate after 15 years which means that the program will stop accepting claims on June 3, 2019. All claims, documents, and submissions must be sent to the Settlement Facility on or before June 3, 2019. They must be postmarked on or before June 3, 2019 or they will not be considered. There will be no extensions.
You may receive or may have previously received a letter from the Settlement Facility giving you a deadline to cure deficiencies in a claim. The June 3, 2019 final deadline DOES NOT CHANGE any deadline in a letter from the Settlement Facility. If you have any questions about your deadline, contact the Settlement Facility. If you do not comply with your deadline, your claim will be denied.
Go to the SF-DCT website or contact the Settlement Facility for information about your claim and rights. The Settlement Facility has posted a Notice with details about: how to apply for either the Expedited Release or Disease Payment, how to apply for an Increased Severity disease claim, how to submit an appeal to the Claims Administrator and Appeals Judge, and how to get claim forms and other information to help you file a claim. All documents and forms are on the websites below or call the Settlement Facility to get any form or document mailed to you. Please keep your address current.
Settlement Facility Contact Information:
Website: www.sfdct.com or www.dcsettlement.com
Mailing address: Settlement Facility; P.O. Box 52429; Houston, TX 77052-2429
FINAL DEADLINE: JUNE 3, 2019. NO EXTENSIONS.
FEBRUARY 5, 2018
The Settlement Facility mailed a letter last week letting everyone who filed a Proof of Claim in the Dow Corning bankruptcy know that the Settlement Facility will be terminating the settlement program next year. The Settlement Facility was originally set up to begin paying claims in 2004 and to last for 15 years. The end of that 15 year period is June 3, 2019. All claims must be submitted on or before June 3, 2019 or they will be barred. We know that many of you may have questions about what this means, so we have developed a Q&A (Questions and Answers) that can provide you with information. The Q&As are posted on this website under the tab called “Claimant Information Guide and Questions and Answers.” Click on the link that says “Q&As about the Closing of the Settlement Facility.”
The Settlement Facility office will not close on June 3, 2019. This is a deadline to file claims and submit any and all documents to have a claim reviewed and paid. The Settlement Facility office will remain open to review and process all claims until all approved claims have been paid.
The final Premium Payment for approved Rupture and Disease claims, as well as approved Increased Severity disease claims, will likely be made sometime after the June 3, 2019 deadline when all claims have been reviewed. This may take several months or longer to complete, so it is more likely that any Premium Payment would be made in 2020.